Elisabeth Bendstrup

The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Standard

The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. / Hoffmann-Vold, Anna Maria; Allanore, Yannick; Bendstrup, Elisabeth; Bruni, Cosimo; Distler, Oliver; Maher, Toby M.; Wijsenbeek, Marlies; Kreuter, Michael.

In: Respiratory Research, Vol. 21, No. 1, 07.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review

Harvard

Hoffmann-Vold, AM, Allanore, Y, Bendstrup, E, Bruni, C, Distler, O, Maher, TM, Wijsenbeek, M & Kreuter, M 2020, 'The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease', Respiratory Research, vol. 21, no. 1. https://doi.org/10.1186/s12931-020-01459-0

APA

Hoffmann-Vold, A. M., Allanore, Y., Bendstrup, E., Bruni, C., Distler, O., Maher, T. M., Wijsenbeek, M., & Kreuter, M. (2020). The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respiratory Research, 21(1). https://doi.org/10.1186/s12931-020-01459-0

CBE

Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, Wijsenbeek M, Kreuter M. 2020. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respiratory Research. 21(1). https://doi.org/10.1186/s12931-020-01459-0

MLA

Vancouver

Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM et al. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respiratory Research. 2020 Jul;21(1). https://doi.org/10.1186/s12931-020-01459-0

Author

Hoffmann-Vold, Anna Maria ; Allanore, Yannick ; Bendstrup, Elisabeth ; Bruni, Cosimo ; Distler, Oliver ; Maher, Toby M. ; Wijsenbeek, Marlies ; Kreuter, Michael. / The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. In: Respiratory Research. 2020 ; Vol. 21, No. 1.

Bibtex

@article{921952c344814b0aab01b4b5974f2ecb,
title = "The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease",
abstract = "Systemic sclerosis (SSc) is a multi-organ autoimmune disease with complex interactions between immune-mediated inflammatory processes and vascular pathology leading to small vessel obliteration, promoting uncontrolled fibrosis of skin and internal organs. Interstitial lung disease (ILD) is a common but highly variable manifestation of SSc and is associated with high morbidity and mortality. Treatment approaches have focused on immunosuppressive therapies, which have shown some efficacy on lung function. Recently, a large phase 3 trial showed that treatment with nintedanib was associated with a reduction in lung function decline. None of the conducted randomized clinical trials have so far shown convincing efficacy on other outcome measures including quality of life determined by patient reported outcomes. Little evidence is available for non-pharmacological treatment and supportive care specifically for SSc-ILD patients, including pulmonary rehabilitation, supplemental oxygen, symptom relief and adequate information. Improved management of SSc-ILD patients based on a holistic approach is necessary to support patients in maintaining as much quality of life as possible throughout the disease course and to improve long-term outcomes.",
keywords = "Fibrosis, Interstitial lung disease, Systemic sclerosis, Treatment",
author = "Hoffmann-Vold, {Anna Maria} and Yannick Allanore and Elisabeth Bendstrup and Cosimo Bruni and Oliver Distler and Maher, {Toby M.} and Marlies Wijsenbeek and Michael Kreuter",
year = "2020",
month = jul,
doi = "10.1186/s12931-020-01459-0",
language = "English",
volume = "21",
journal = "Respiratory Research Review",
issn = "1178-6205",
publisher = "Research Review Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease

AU - Hoffmann-Vold, Anna Maria

AU - Allanore, Yannick

AU - Bendstrup, Elisabeth

AU - Bruni, Cosimo

AU - Distler, Oliver

AU - Maher, Toby M.

AU - Wijsenbeek, Marlies

AU - Kreuter, Michael

PY - 2020/7

Y1 - 2020/7

N2 - Systemic sclerosis (SSc) is a multi-organ autoimmune disease with complex interactions between immune-mediated inflammatory processes and vascular pathology leading to small vessel obliteration, promoting uncontrolled fibrosis of skin and internal organs. Interstitial lung disease (ILD) is a common but highly variable manifestation of SSc and is associated with high morbidity and mortality. Treatment approaches have focused on immunosuppressive therapies, which have shown some efficacy on lung function. Recently, a large phase 3 trial showed that treatment with nintedanib was associated with a reduction in lung function decline. None of the conducted randomized clinical trials have so far shown convincing efficacy on other outcome measures including quality of life determined by patient reported outcomes. Little evidence is available for non-pharmacological treatment and supportive care specifically for SSc-ILD patients, including pulmonary rehabilitation, supplemental oxygen, symptom relief and adequate information. Improved management of SSc-ILD patients based on a holistic approach is necessary to support patients in maintaining as much quality of life as possible throughout the disease course and to improve long-term outcomes.

AB - Systemic sclerosis (SSc) is a multi-organ autoimmune disease with complex interactions between immune-mediated inflammatory processes and vascular pathology leading to small vessel obliteration, promoting uncontrolled fibrosis of skin and internal organs. Interstitial lung disease (ILD) is a common but highly variable manifestation of SSc and is associated with high morbidity and mortality. Treatment approaches have focused on immunosuppressive therapies, which have shown some efficacy on lung function. Recently, a large phase 3 trial showed that treatment with nintedanib was associated with a reduction in lung function decline. None of the conducted randomized clinical trials have so far shown convincing efficacy on other outcome measures including quality of life determined by patient reported outcomes. Little evidence is available for non-pharmacological treatment and supportive care specifically for SSc-ILD patients, including pulmonary rehabilitation, supplemental oxygen, symptom relief and adequate information. Improved management of SSc-ILD patients based on a holistic approach is necessary to support patients in maintaining as much quality of life as possible throughout the disease course and to improve long-term outcomes.

KW - Fibrosis

KW - Interstitial lung disease

KW - Systemic sclerosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85088530602&partnerID=8YFLogxK

U2 - 10.1186/s12931-020-01459-0

DO - 10.1186/s12931-020-01459-0

M3 - Review

C2 - 32703199

AN - SCOPUS:85088530602

VL - 21

JO - Respiratory Research Review

JF - Respiratory Research Review

SN - 1178-6205

IS - 1

ER -